Identification and validation of novel engineered AAV capsid variants targeting human glia
(2024) In Frontiers in Neuroscience 18.- Abstract
Direct neural conversion of endogenous non-neuronal cells, such as resident glia, into therapeutic neurons has emerged as a promising strategy for brain repair, aiming to restore lost or damaged neurons. Proof-of-concept has been obtained from animal studies, yet these models do not efficiently recapitulate the complexity of the human brain, and further refinement is necessary before clinical translation becomes viable. One important aspect is the need to achieve efficient and precise targeting of human glial cells using non-integrating viral vectors that exhibit a high degree of cell type specificity. While various naturally occurring or engineered adeno-associated virus (AAV) serotypes have been utilized to transduce glia, efficient... (More)
Direct neural conversion of endogenous non-neuronal cells, such as resident glia, into therapeutic neurons has emerged as a promising strategy for brain repair, aiming to restore lost or damaged neurons. Proof-of-concept has been obtained from animal studies, yet these models do not efficiently recapitulate the complexity of the human brain, and further refinement is necessary before clinical translation becomes viable. One important aspect is the need to achieve efficient and precise targeting of human glial cells using non-integrating viral vectors that exhibit a high degree of cell type specificity. While various naturally occurring or engineered adeno-associated virus (AAV) serotypes have been utilized to transduce glia, efficient targeting of human glial cell types remains an unsolved challenge. In this study, we employ AAV capsid library engineering to find AAV capsids that selectively target human glia in vitro and in vivo. We have identified two families of AAV capsids that induce efficient targeting of human glia both in glial spheroids and after glial progenitor cell transplantation into the rat forebrain. Furthermore, we show the robustness of this targeting by transferring the capsid peptide from the parent AAV2 serotype onto the AAV9 serotype, which facilitates future scalability for the larger human brain.
(Less)
- author
- Giacomoni, Jessica
LU
; Åkerblom, Malin
LU
; Habekost, Mette
LU
; Fiorenzano, Alessandro LU ; Kajtez, Janko LU
; Davidsson, Marcus LU ; Parmar, Malin LU
and Björklund, Tomas LU
- organization
-
- Developmental and Regenerative Neurobiology (research group)
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- LTH Profile Area: Engineering Health
- MultiPark: Multidisciplinary research focused on Parkinson's disease
- Molecular Neuromodulation (research group)
- Behavioural Neuroscience Laboratory (research group)
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- 3D culture, AAV engineering, BRAVE library, ex vivo brain slices, hGPCs, neuroscience
- in
- Frontiers in Neuroscience
- volume
- 18
- article number
- 1435212
- publisher
- Frontiers Media S. A.
- external identifiers
-
- pmid:39193523
- scopus:85202159749
- ISSN
- 1662-4548
- DOI
- 10.3389/fnins.2024.1435212
- language
- English
- LU publication?
- yes
- id
- 0751e51f-7c71-4791-8a55-97bbbafc35d1
- date added to LUP
- 2024-11-01 09:22:56
- date last changed
- 2025-07-12 08:03:05
@article{0751e51f-7c71-4791-8a55-97bbbafc35d1, abstract = {{<p>Direct neural conversion of endogenous non-neuronal cells, such as resident glia, into therapeutic neurons has emerged as a promising strategy for brain repair, aiming to restore lost or damaged neurons. Proof-of-concept has been obtained from animal studies, yet these models do not efficiently recapitulate the complexity of the human brain, and further refinement is necessary before clinical translation becomes viable. One important aspect is the need to achieve efficient and precise targeting of human glial cells using non-integrating viral vectors that exhibit a high degree of cell type specificity. While various naturally occurring or engineered adeno-associated virus (AAV) serotypes have been utilized to transduce glia, efficient targeting of human glial cell types remains an unsolved challenge. In this study, we employ AAV capsid library engineering to find AAV capsids that selectively target human glia in vitro and in vivo. We have identified two families of AAV capsids that induce efficient targeting of human glia both in glial spheroids and after glial progenitor cell transplantation into the rat forebrain. Furthermore, we show the robustness of this targeting by transferring the capsid peptide from the parent AAV2 serotype onto the AAV9 serotype, which facilitates future scalability for the larger human brain.</p>}}, author = {{Giacomoni, Jessica and Åkerblom, Malin and Habekost, Mette and Fiorenzano, Alessandro and Kajtez, Janko and Davidsson, Marcus and Parmar, Malin and Björklund, Tomas}}, issn = {{1662-4548}}, keywords = {{3D culture; AAV engineering; BRAVE library; ex vivo brain slices; hGPCs; neuroscience}}, language = {{eng}}, publisher = {{Frontiers Media S. A.}}, series = {{Frontiers in Neuroscience}}, title = {{Identification and validation of novel engineered AAV capsid variants targeting human glia}}, url = {{http://dx.doi.org/10.3389/fnins.2024.1435212}}, doi = {{10.3389/fnins.2024.1435212}}, volume = {{18}}, year = {{2024}}, }